Gemifloxacin FDA Link

A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.

Also Known As:

Factive; 7- (3- aminomethyl- 4- methoxyimino- pyrrolidine- 1- yl)- 1- cyclopropyl- 6- fluoro- 4- oxo- 1,4- dihydro- (1,8)- naphthyridine- 3- carboxylic acid; Gemifloxacin Mesylate; LB 20304; LB-20304; LB20304; SB 265805; SB-265805; SB265805; 1,8-Naphthyridine-3-carboxylic acid, 7- ((4Z)- 3- (aminomethyl)- 4- (methoxyimino)- 1- pyrrolidinyl)- 1- cyclopropyl- 6- fluoro- 1,4- dihydro- 4- oxo-

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        Fluoroquinolones: 5348
        Gemifloxacin: 138
    - Naphthyridines: 2
      - Gemifloxacin: 138

Kerin Tyrrell Selected Research

Kerin Tyrrell Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure